- Conditions
- Advanced Cancer, Metastatic Cancer
- Interventions
- Mocaciclib (Q901), KEYTRUDA® (pembrolizumab), Fulvestrant
- Drug
- Lead sponsor
- Qurient Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • Los Angeles, California • Jacksonville, Florida + 4 more
Clinical trials in Dallas, Texas
This page shows live ClinicalTrials.gov search results for Dallas, Texas, with direct links to official study records plus on-page filtering and sorting for broad location searches.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Institutions in Dallas
Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.
Live official records
Open in full search- Conditions
- Partial Lipodystrophy
- Interventions
- metreleptin, Placebo
- Drug
- Lead sponsor
- Chiesi Farmaceutici S.p.A.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Sacramento, California • Boca Raton, Florida + 9 more
- Conditions
- Ischemic Stroke, Sleep Apnea, Sleep Apnea, Obstructive, Stroke, CPAP, Telemedicine, Home Sleep Apnea Test, Randomized Clinical Trial, Multicenter Trial
- Interventions
- CPAP
- Device
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,892 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 116
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 94 more
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, Gemcitabine, Paclitaxel, Intismeran autogene, Placebo
- Biological · Drug · Other
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 680 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2038
- U.S. locations
- 54
- States / cities
- Gilbert, Arizona • Tucson, Arizona • Fullerton, California + 42 more
- Conditions
- Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
- Interventions
- BI 4015092, Cetuximab
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 3
- States / cities
- New Haven, Connecticut • Dallas, Texas • Houston, Texas
- Conditions
- Multiple Sclerosis
- Interventions
- Frexalimab, Placebo, MRI contrast-enhancing agents
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 943 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 79
- States / cities
- Homewood, Alabama • Scottsdale, Arizona • Berkeley, California + 68 more
- Conditions
- Primary Membranous Nephropathy
- Interventions
- Felzartamab, Tacrolimus, Standard of Care IST
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 16
- States / cities
- Huntsville, Alabama • Fresno, California • Los Angeles, California + 12 more
- Conditions
- Metabolic Dysfunction-Associated Steatohepatitis, MASH
- Interventions
- ALN-CIDEB, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 360 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 22
- States / cities
- Tucson, Arizona • Pasadena, California • Rialto, California + 16 more
- Conditions
- Cystic Fibrosis-related Diabetes
- Interventions
- iLet Bionic Pancreas System (BP), Usual Care (UC)
- Device
- Lead sponsor
- Jaeb Center for Health Research
- Other
- Eligibility
- 14 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 16
- States / cities
- Aurora, Colorado • New Haven, Connecticut • Atlanta, Georgia + 13 more
- Conditions
- Breast Cancer, Metastatic
- Interventions
- Evorpacept (ALX148), Trastuzumab, Paclitaxel, Capecitabine, Eribulin, Gemcitabine, Vinorelbine
- Drug
- Lead sponsor
- ALX Oncology Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 28
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Duarte, California + 24 more
- Conditions
- Obesity, Overweight
- Interventions
- Maridebart cafraglutide, Autoinjector
- Drug · Device
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 24
- States / cities
- San Diego, California • Miami, Florida • Orlando, Florida + 17 more
- Conditions
- Homocystinuria
- Interventions
- Pegtibatinase, Placebo
- Drug · Other
- Lead sponsor
- Travere Therapeutics, Inc.
- Industry
- Eligibility
- 12 Years to 65 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • New Haven, Connecticut • Atlanta, Georgia + 10 more